Publication

Predictors of Central Venous Catheter Use at the Initiation of Hemodialysis

Downloadable Content

Persistent URL
Last modified
  • 02/20/2025
Type of Material
Authors
    Haimanot Wasse, Emory UniversityRebecca A. Speckman, Emory UniversityDiane L. Frankenfield, Centers for Medicare & Medicaid ServicesMichael V. Rocco, Wake Forest UniversityWilliam McClellan, Emory University
Language
  • English
Date
  • 2008
Publisher
  • Wiley: 12 months
Publication Version
Copyright Statement
  • © 2008 Copyright the Authors. Journal compilation © 2008 Wiley Periodicals, Inc.
Final Published Version (URL)
Title of Journal or Parent Work
ISSN
  • 0894-0959
Volume
  • 21
Issue
  • 4
Start Page
  • 346
End Page
  • 351
Grant/Funding Information
  • National Institute of Diabetes and Digestive and Kidney Diseases : NIDDK
  • This work was supported in part by a National Institutes of Health Career Development Award K23 DK65634 (H.W.).
Abstract
  • Central venous catheter (CVC) use at hemodialysis (HD) initiation remains high, despite reports of CVC-associated morbidity and mortality, and efforts at early arteriovenous fistula placement. In order to determine predictors of CVC use at the start of HD, data from the end-stage renal disease (ESRD) Clinical Performance Measures (CPM) Project was linked to the Centers for Medicare & Medicaid Services Medical Evidence (2728) Form. Of the 4071 incident hemodialysis patients in study years 1999–2003, 71.6% used a CVC at dialysis initiation. After controlling for demographic and co-morbid variables, patients with a CVC were 24% more likely to be female (p = 0.006), and 38% more likely to have ischemic heart disease (p = 0.002), while those with obesity (BMI ≥30) were 24% less likely to start dialysis with a CVC (p = 0.006). Pre-ESRD hypoalbuminemia (< 3.5 g/dl) was associated with a twofold higher risk of CVC use (p = <0.001), while patients with pre-ESRD anemia (hgb < 11 g/dl) were 29% more likely to use a CVC at dialysis initiation (p = 0.006) compared to those with hemoglobin ≥11 g/dl. Patients receiving predialysis erythropoietin had a 41% lower odds of CVC use at dialysis initiation (p = <0.001). Finally, dialysis year was predictive of CVC use; in 2002, 76% of patients initiated dialysis with a CVC compared with 66% in 1998 (p < 0.001). Overall, female gender, ischemic heart disease, lack of obesity, factors suggesting poor pre-ESRD care, and successive year of dialysis initiation were predictive of CVC use at hemodialysis initiation.
Author Notes
  • Address correspondence to: Haimanot Wasse, MD, MPH, Division of Nephrology System, Emory University, WMB Room 338, 1639 Pierce Drive, Atlanta, GA 30322, or e-mail: hwasse@emory.edu
Research Categories
  • Health Sciences, Epidemiology

Tools

Relations

In Collection:

Items